New cytotoxics and non-cytotoxics in epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 10, Issue SUPPL. 1, 2000, Pages 38-43

  Eisenhauer, E A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

New drugs; Non cytotoxics; Ovarian cancer

Indexed keywords

DOXORUBICIN; EPIRUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM; TOPOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL;

EID: 0033995280     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2000.99509.x     Document Type: Article

References (40)

1. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
2. Stuart G, Bertelson K, Mangioni C et al. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup Trial. Proc Am Soc Clin Oncol 1998; 17: 361a.
3. Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of docetaxel (Taxotere®) in advanced ovarian cancer - an updated overview. Eur J Cancer 1997; 33: 2167-70.
4. Dancey J, Eisenhauer EA. Current Perspectives on camptothecins in cancer treatment. Br J Cancer 1996; 74: 327-38.
5. Bookman MA, Malstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16: 3345-52.
6. Gordon A, Carmichael J, Malfetano J et al. Final analysis of a phase III, randomized study of topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian carcinoma (OC): International Topotecan Study Group. Proc Am Soc Clin Oncol 1998; 17: 356a (abstract).
7. Kudelka AP, Tresukosol D, Edwards CL et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory ovarian carcinoma. J Clin Oncol 1996; 14: 1552-7.
8. Armstrong D, Rowinsky E, Donehower R, Rosenshein N, Walczak J, McGuire W. A phase II trial of topotecja as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 275 (abstract).
9. Hoskins P, Eisenhauer E, Beare S et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998; 16: 2233-7.
10. Gore M, Rustin G, Calvert H et al. A multicentre, randomised, phase in study of topotecan (T) administered intravenously or orally for advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: 349a (abstract).
11. Miller AA, Hargis JB, Lilenbaum RC et al. Phase I study of topotecan and cisplatin in patients with advanced solid tumors. J Clin Oncol 1994; 12: 2743-50.
12. O'Reilly S, Fleming GF, Baker SD et al. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated epithelial ovarian malignancies. A Gynecologic Oncology Group Study. J Clin Oncol 1997; 15: 177-86.
13. Herben VMM, Nannon Panday VR, Richel DJ et al. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin and topotecan administered intravenously every 21 days as first-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 1999; 17: 747-55.
14. Scarfone G, Bolis G, Villa A et al. Phase I-II sequential topotecan (TPT) chemotherapy in patients (pts) with small residual disease after Taxol-carboplatin (TC) as first line chemotherapy in advanced epithelial ovarian cancer (AEOC). Proc Am Soc Clin Oncol 1998; 17: 362a (abstract).
15. Hoskins P, Eisenhauer E, Fisher B et al. Sequential couplets of cisplatin (DDP) /topotecan (TOP) and cisplatin/ Paclitaxel (T) as first-line therapy for advanced epithelial ovarian cancer (EOC): an NCIC Clinical Trials Group phase II study. Proc Am Soc Clin Oncol 1999; 18: 357a (abstract).
16. Lund B, Hansen OP, Theilade K et al. Phase II study of gemcitabine (2′,2′ difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-3.
17. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89-93.
18. Poole CJ, Perren T, Hogberg T et al. Phase I study to investigate the optimal dose and schedule of gemcitabine (G) and paclitaxel (P) in combination in patients with previously treated epithelial ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: 357a (abstract).
19. Krakowski I, Petit T, Kayitalire L et al. Gemcitabine (Gemzar®) in combination with cisplatin (CP) in advanced ovarian cancer (AOC): a phase II study. Proc Am Soc Clin Oncol 1998; 17: 356a (abstract).
20. Bauknecht T, Grieshaber C, Breitbach G-P et al. Gemcitabine (GEM) in combination with cisplatin (CP) in previously untreated patients > 60 years with FIGO stage IIIC or IV epithelial ovarian cancer: a phase II study: preliminary results. Proc Am Soc Clin Oncol 1998; 17: 356a (abstract).
21. Nogue M, Cirera L, Arcusa M et al. Gemcitabine combined with cisplatin first line: a phase II study in patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: 357a (abstract).
22. Hansen SW, Anderson H, Boman K et al. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc Am Soc Clin Oncol 1999; 18: 357a. (abstract).
23. Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. Classic Papers and Current Comments 1998; 3: 237-43.
24. Du Bois A, Luck HJ, Bauknecht T et al. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a Phase I/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. J Clin Oncol 1999; 17: 46-51.
25. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-93.
26. Rose P, Gordon AN, Granai CO et al. Interim analysis of a non-comparative multicentre study of DOXIL/ CAELYX in the treatment of patients with refractory ovarian cancer. Proc Am Soc Clin Oncol 1999; 18: 360a (abstract).
27. Isreal VK, Jeffers S, Bernal G et al. Phase I study of Doxil (liposomal doxorubicin) in combination with paclitaxel. Proc Am Soc Clin Oncol 1997; 16: 239a (abstract).
28. Slamon DJ, Godolphin W, Jones A et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
29. Slamon D, Leyland-Jones B, Shark S et al. Addition of herceptin to first line chemotherapy for HER-2 overexpressing metastatic breast cancer markedly increases anticancer activity. A randomized controlled phase III trial. Proc Am Soc Clin Oncol 1998; 17: 98a (abstract).
30. Sikic B, Yuen A, Halsey J et al. Phase I trial of an antisense oligonucleotide targeted to PKC′, delivered by a 21-day continuous infusion. Proc Am Soc Clin Oncol 1997; 16: 212a (abstract).
31. Hannah A, Malkin M, Rosen L et al. An overview of phase I/II studies of SU101, a tyrosine kinase inhibitor. Ann Oncol 1998; 9 (Suppl. 2): 18 (abstract).
32. Davies B, Brown PD, East N et al. A synthetic MMPI decreases tumour burden and prolongs survival of mice bearing human ovarian cancer xenografts. Cancer Res 1993; 53: 2087-91.
33. Nemunaitis J, Poole C, Primrose J et al. Combined analysis of studies of the effects of matrix metalloproteinase inhibitor marimastat on serum tumour markers in advanced cancer. Selection of a biologically active and tolerable dose for long-term studies. Clin Cancer Res 1998; 4: 1101-9.
34. Rowinsky E, Hammond L, Aylesworth C et al. Prolonged administration of BAY 12-9566 - an oral MMP inhibitor, a phase I and PK study. Proc Am Soc Clin Oncol 1998; 17: 216a (abstract).
35. Heise C, Sampson-Johannes A, Willams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B geneattenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 1997; 3: 639-45.
36. Heise CC, Williams AM, Xue S, Propst M, Kirn DH. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res 1999; 59: 2623-8.
37. Roth JA, Nguyen D, Lawrence DD et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996; 2: 985-91.
38. Swisher SG, Roth JA, Nemunaitis J et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 763-71.
39. Kaye S, Nemunaitis J, Ganly I et al. Phase II trial of intratumoral injection of an E1B deleted adenovirus, Onyx-015, in patients with recurrent refractory head and neck cancer. Ann Oncol 1998; 9 (Suppl. 2): 22 (abstract).
40. Kirn D, Ganly I, Sampson-Johannes A et al. Onyx-015, a selectively replicating E1B-deleted adenovirus, has significant activity against human ovarian carcinoma alone and in combination with standard chemotherapeutic agents. Proc Am Soc Clin Oncol 1998; 17: 211a (abstract).